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Abstract
A number of transcription factors were revealed in the study of chromosomal 
translocation associated with T cell acute lymphoblastic leukemia.  LYL1 is one of 
the examples of such transcription factors. LYL1 is a member of the class II basic 
helix-loop-helix transcription factors and aberrantly expressed in a fraction of 
human T cell acute lymphoblastic leukemia. The mechanism of leukemogenesis by 
 LYL1 has been studied in transgenic mouse ubiquitously overexpressing  LYL1 
using a construct expressing full-length cDNA driven by a human elongation factor 
l  promoter. 30% of these transgenic mice developed malignant lymphoma with an 
average latent period of 352 days. Lymphomas developed are both B and T cell 
lymphomas. LYL1 forms a heterodimer with another basic helix-loop-helix protein 
E2A. Overexpressed LYL1 inhibits the  E2A/HEB heterodimer formation, thus 
inactivates the physiological function of E2A, which might be the essential step to 
leukemogenesis.
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 LYL1 belongs to the class II basic helix-
loop-helix transcription factor family. It 
was first identified at chromosomal trans-
location loci [t(7;  19)(q35;  p13)] from a hu-
man T cell leukemia cell line, and ectopic 
expression of LYL1 observed in a fraction 
of human T cell acute lymphoblastic leuke-
mia (ALL) (Mellentin et al.,1989; Ferrando 
et al.,2002; Ferrando and Look, 2003). The 
basic helix-loop-helix sequence of LYL1 
shows remarkable similarity with those of 
 TAL1 (also known as SCL) and TAL2. 
 TAL1 and TAL2 were also identified at 
the breakpoints of chromosomal transloca-
tion of T cell acute lymphoblastic leuke-
mia. Biological role of  LYL1 remains large-
ly unknown but it can bind to another 
basic helix-loop-helix protein E2A. The ex-
pression of  LYL1 is restricted to hematopoi-
etic cells, especially mature B lymphocytes 
 (Visvader et al.,  1991; Kuo et al.,  1991). 
 In order to know the leukemogenic mech-
anism of LYL1, transgenic mice which 
were overexpressing  LYL1 has been made 
(Zhong et al., 2007). In these mice, the hu-
man elongation factor l   promoter  (EF-l )
drove the expression of  LYL1 ubiquitously. 
Unlike wild-type mice, the expression of 
 LYL1 in thymus was observed in these tra-
nsgenic mice. These mice exhibited short 
kinked tails and a loss of hair. Thirty per-
cent of the transgenic mice developed both 
B cell and T cell lymphoma after relatively 
long latent period (average 352 days).
E2A forms a heterodimer with overexpressed 
 LYL1, which inhibits the normal function of 
E2A
 E2A is another basic helix-loop-helix protein 
which has an essential role in normal devel-
opment of lymphocytes. In T lymphocytes, E2 
A interacts with HEB, a member of Class I 
basic helix-loop-helix family and activates 
target genes (like CD4). On the other hand, in 
B lymphocytes, E2A functions through the 
formation of a homodimer to regulate down-
stream genes (Lazorchak et al., 2005; Murre, 
2005). Because LYL1 can interact with E2A 
protein, Overexpressed  LYL1 can form a 
heterodimer with E2A, thus inhibit the 
physiological function of E2A in the normal
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development of lymphocytes. Zhong et al. 
studied the effect of LYL1 on dimerization of 
E2A using mammalian two-hybrid assay. In 
this study, the formation of both E2A 
homodimer and E2A/HEB heterodimer was 
blocked by  LYL1 in a dose-dependent manner 
(Zhong et al., 2007). Because E2A knock-out 
mice produce T cell lymphoma (Bain et al., 
1997; Yan et al., 1997), inhibition of E2A
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function seems to lead to the leukemogenesis. 
Therefore, it is possible to consider that 
overexpressed  LYL1 partially disrupt the 
normal function of E2A, which lead to the 
development of lymphoma. 
 LYL1 also inhibits regulatory function of 
E2A/HEB heterodimer. E2A regulates the 
expression of target genes through binding 
to an E-box consensus sequence. For exam-
Fig. 1 Development of malignant lymphoma in  LYL1 transgenic mice 
(a) Representative X-ray photograph (left) and Alizarin red staining (right) 
of tail. TG, transgenic mice of  11 months; Wt, wild type of  11 months; 
white arrows, misformed vertebrae. (b) Survival curve for the offspring of 
four independent lines of LYL1 transgenic mice and wild type control (Wt, 
wild type; NTL, non-transgenic littermates;  *P<  0.001 with Kaplan Meiyer 
analysis). (c) Histology of involved organs in case of T-cell lymphoma 
 (#2644). Thy, thymus; LN, lymph node; SPN, spleen; LV, liver; K, kidney 
 (Bar=100um,  25um at the inset).
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 ple, CD4 transcription is activated by E2A, 
which forms a complex with HEB and 
binds to the E-box element of the CD4 en-
hancer (Sawada and Littman, 1993). Zhong 
et al. studied the effect of LYL1 on the reg-
ulatory activity of E2A/HEB. A firefly  lu-
ciferase reporter vector driven by a CD4 en-
hancer-promoter was transfected into 293T 
cells with vectors expressing LYL1, E2A, 
 TAL1 or HEB in various combinations. 
The luciferase activity was activated most-
ly when the reporter vector was trans-
fected with the combination of E2A and 
HEB. It was suppressed when HEB was 
substituted by  LYL1 or  TAL1.
Conclusion
 LYL1 has a function to form malignant 
lymphomas when it is expressed in transgenic 
mouse. Although the direct target genes of 
LYL1 are not revealed at present, it developed 
B- and T-cell lymphoma by inhibiting the role 
of another basic helix-loop-helix protein E2A. 
Identification of LYL1 target genes is the most 
important step to fully understand the real 
leukemogenic function of  LYL1.
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